Guardant Health GH Business Segments — Cost of precision oncology testing
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Guardant Health in its filing.
Tagged under the XBRL concept gh:CostsOfPrecisionOncologyTestingAdjusted.
The official record: Guardant Health’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Guardant Health's business segments — cost of precision oncology testing.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Guardant Health's business segments — cost of precision oncology testing?
- Guardant Health (GH) reported business segments — cost of precision oncology testing of $84.3M in Q4 2025.
- How has Guardant Health's business segments — cost of precision oncology testing changed year-over-year?
- Guardant Health's business segments — cost of precision oncology testing increased by 20.7% year-over-year, from $69.86M to $84.3M.
- What is the long-term trend for Guardant Health's business segments — cost of precision oncology testing?
- Over 3 years (2022 to 2025), Guardant Health's business segments — cost of precision oncology testing has grown at a 33.5% compound annual growth rate (CAGR), from $141.69M to $337.2M.
- What does business segments — cost of precision oncology testing mean?
- This represents the specific direct costs attributable to the laboratory processing and clinical reporting of precision oncology diagnostic tests. It is a subset of the total cost of revenue focused on the core testing business.